
Quanterix Corp — Investor Relations & Filings
Quanterix Corporation is a company focused on digitizing biomarker analysis to advance the science of precision health. Its core offering is the proprietary Simoa® technology, an ultra-sensitive digital immunoassay platform designed to detect and measure biomarkers at extremely low concentrations. This capability allows researchers to study the biology of health and disease with high precision, enabling earlier disease detection, improved prognoses, and the development of more effective treatment methods. The Simoa platform is utilized across a wide range of therapeutic areas, including a strategic focus on neurology (neurodegeneration, neuroinflammation, traumatic brain injuries), as well as oncology, cardiology, inflammation, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | |
| ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | |
| 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | |
| 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41998200 | 8-K - Quanterix Corp (0001503274) (Filer) | 2026-05-06 | English | ||
| 36127788 | ARS - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 36127820 | DEF 14A - Quanterix Corp (0001503274) (Filer) | 2026-04-24 | English | ||
| 33034998 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-24 | English | ||
| 32968563 | 4 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32968562 | 3 - Quanterix Corp (0001503274) (Issuer) | 2026-03-17 | English | ||
| 32892834 | 10-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892833 | 8-K - QUANTERIX CORP (0001503274) (Filer) | 2026-03-02 | English | ||
| 32892832 | 4 - QUANTERIX CORP (0001503274) (Filer) | 2026-02-18 | English | ||
| 30191110 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30191109 | 4 Filing | 2026-02-06 | English | ||
| 30191105 | 4 Filing | 2026-01-21 | English | ||
| 30191104 | 3 Filing | 2026-01-21 | English | ||
| 30191111 | 4 Filing | 2026-01-20 | English | ||
| 30191086 | 4 Filing | 2026-01-20 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.
Integrated CRO providing full-spectrum R&D from drug discov…
|
688621 | CN | Professional, scientific and te… |
|
BenevolentAI
Applies artificial intelligence to accelerate drug discover…
|
BAI | LU | Professional, scientific and te… |
|
Berry Genomics Co.,Ltd
Provides clinical genomics and genetic testing for prenatal…
|
000710 | CN | Professional, scientific and te… |
|
BetterLife Pharma
Developing non-hallucinogenic neuroplastogens for severe ne…
|
BETR | CA | Professional, scientific and te… |
|
BGI Genomics Co., Ltd.
Provides integrated solutions for precision medicine via ge…
|
300676 | CN | Professional, scientific and te… |
|
bioAffinity Technologies, Inc.
Develops noninvasive diagnostics and targeted therapeutics …
|
BIAF | US | Professional, scientific and te… |
|
BioArctic
Biopharmaceutical firm developing antibody therapies for ne…
|
BIOA | SE | Professional, scientific and te… |
|
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Develops antibody therapeutics using proprietary RenMice ge…
|
688796 | CN | Professional, scientific and te… |
|
BIO-GENE TECHNOLOGY LTD
Develops novel insecticides from natural chemistry to comba…
|
BGT | AU | Professional, scientific and te… |
|
BioInfra Co.,Ltd.
Develops multi-biomarker blood tests for early cancer scree…
|
199730 | KR | Professional, scientific and te… |
Quanterix Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33531/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33531 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33531 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33531 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33531}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Quanterix Corp (id: 33531)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.